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Abstract
Heterozygous mutations in the PRPF31 gene cause autosomal dominant retinitis pigmentosa (adRP), a hereditary disorder
leading to progressive blindness. In some cases, such mutations display incomplete penetrance, implying that certain
carriers develop retinal degeneration while others have no symptoms at all. Asymptomatic carriers are protected from the
disease by a higher than average expression of the PRPF31 allele that is not mutated, mainly through the action of an
unknown modifier gene mapping to chromosome 19q13.4. We investigated a large family with adRP segregating an 11-bp
deletion in PRPF31. The analysis of cell lines derived from asymptomatic and affected individuals revealed that the
expression of only one gene among a number of candidates within the 19q13.4 interval significantly correlated with that of
PRPF31, both at the mRNA and protein levels, and according to an inverse relationship. This gene was CNOT3, encoding a
subunit of the Ccr4-not transcription complex. In cultured cells, siRNA–mediated silencing of CNOT3 provoked an increase in
PRPF31 expression, confirming a repressive nature of CNOT3 on PRPF31. Furthermore, chromatin immunoprecipitation
revealed that CNOT3 directly binds to a specific PRPF31 promoter sequence, while next-generation sequencing of the
CNOT3 genomic region indicated that its variable expression is associated with a common intronic SNP. In conclusion, we
identify CNOT3 as the main modifier gene determining penetrance of PRPF31 mutations, via a mechanism of transcriptional
repression. In asymptomatic carriers CNOT3 is expressed at low levels, allowing higher amounts of wild-type PRPF31
transcripts to be produced and preventing manifestation of retinal degeneration.
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Introduction
The penetrance of a disease-causing mutation corresponds to
the proportion of individuals who carry such variant and develop
clinical symptoms. In the majority of Mendelian disorders
penetrance is 100%, but incomplete penetrance is far from being
uncommon [1]. Although in medical genetics penetrance is still
largely uncharacterized at the molecular level, it is usually
determined by genetic or epigenetic factors, and sometimes even
by environmental modifiers [2].
Retinitis pigmentosa (RP) is a group of inherited degenerative
diseases of the retina that cause the progressive death of
photoreceptors, the neurons of the eye that are sensitive to light.
Typically, patients affected by RP first suffer from night blindness,
most often during adolescence. Rod and cone photoreceptor cells
start to degenerate from the mid periphery to the far periphery
and the center of the retina, resulting in the so-called tunnel vision.
Later in life, central vision is also lost, leading to legal or complete
blindness [3]. Clinically, RP is a highly-heterogeneous disease,
reflecting not only genetic heterogeneity (mutations in different
genes), but also inter-individual diversity (penetrance and expres-
sivity) [4].
The PRPF31 gene encodes in humans a pre-mRNA processing
factor. In autosomal dominant RP (adRP) due to mutations in
PRPF31 penetrance of the disease can be incomplete. Specifically,
in families with PRPF31 mutations it is not uncommon to observe
the presence of asymptomatic individuals who have affected
parents, affected children, or both [5–8]. Although they carry the
same PRPF31 mutation as their affected relatives, asymptomatic
subjects show no visual impairment, even at older ages, and
normal to slightly reduced electroretinographic recordings [7].
PRPF31 mutations causing adRP are largely null alleles, such as
deletions, nonsenses, or DNA changes leading to premature
termination codons and to mRNA degradation [9–14]. Patients
are therefore hemizygotes for PRPF31, suggesting that the
molecular pathophysiology of the disease is due to the functional
loss of one allele and to haploinsufficiency [10,12,15]. The
ubiquitous expression of PRPF31 has allowed a number of
functional studies to be performed in immortalized lymphoblastoid
cell lines (LCLs) from patients and asymptomatic carriers of
mutations [16–18]. In particular, it has been shown that
penetrance of mutations is due to the differential expression of
the PRPF31 allele that is not inactivated by mutations, in both
symptomatic and asymptomatic individuals. Unlike affected
persons, asymptomatic carriers naturally express high amounts
of functional PRPF31 mRNA, a phenomenon that compensates
for the mutation-induced loss of one allele and prevents
manifestation of symptoms [16–18].
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This variable expression of PRPF31 seems to be present within
the general population [16] and therefore asymptomatic carriers of
mutations would be individuals that by chance are ‘‘high
expressors’’. Furthermore, protection from PRPF31 mutations
(and therefore variable PRPF31 expression) is itself an inheritable
character [16,19]. In an elegant meta-analytic study, McGee et al.
[19] have shown that protective alleles, named isoalleles, are
inherited by carriers of PRPF31 mutations from the parent who
does not transmit the mutation (i.e. they are in trans with respect to
the mutation). Furthermore, such isoalleles would be responsible
for the majority of incomplete penetrance cases, and map to
chromosome 19q13.4, in proximity to PRPF31 itself [19]. The
same study also indicated that these isoalleles were not the only
modulators of PRPF31 penetrance, since some individuals with
discordant phenotypes carried an identical wild-type haplotype for
the isoalleles on chromosome 19. Another genetic element
potentially capable of influencing the penetrance of PRPF31
mutation was later mapped to chromosome 14q21–23 [16].
In this study, we search for and identify the major modifier gene
responsible for penetrance of PRPF31 mutations, through the
analysis of LCLs from a very large family with adRP due to a
PRPF31 microdeletion [6,20].
Results
CNOT3 expression is inversely proportional to that of
PRPF31 in asymptomatic and affected carriers of
mutations
The region on chromosome 19q13.4 harboring the main
modifier gene for PRPF31 penetrance was determined by McGee
et al. to lie between microsatellite markers D19S572 and D19S926
[19]. This interval contains 118 genes, including 50 protein-coding
genes, 50 miRNAs and 18 pseudogenes.
Based on data from lymphoblast studies describing the nature
and the possible mechanism of action of the penetrance modifier
gene [16–18], we selected protein-coding genes that were
consistently expressed in LCLs, as detected by q-PCR (18 genes).
We also excluded some of the genes that in this region belong to
the leukocyte receptor cluster (LRC) and are implicated exclusively
in leukocyte functions. We were left with 10 sequences, namely:
NDUFA3, TFPT, CNOT3, LENG1, MBOAT7, TSEN34, RPS9,
LILRB3, ILT7, and NALP2. We then measured by q-PCR the
mRNA expression levels of these genes in LCLs from 4
asymptomatic and 6 affected individuals from the RP856/AD5
family (Table S1 and Figure S1). All genes showed consistent
expression across the family members. Of these, only CNOT3
showed a statistically significant difference in mRNA expression
between the two groups of individuals (p,0.01) (Figure 1 and
Figure S1). Unexpectedly, CNOT3 trend of expression was the
opposite to that of PRPF31, as it showed lower expression in
asymptomatic than in the affected carriers of PRPF31 mutations
(Figure 1B). This phenomenon was particularly clear when
expression of CNOT3 and PRPF31 were paired by cell lines and
the relevant regression lines calculated (Figure 1C).
Assessment of CNOT3 protein by quantitative western blotting
confirmed the differential expression detected by q-PCR
(Figure 1D).
CNOT3 is a negative regulator of PRPF31 expression
CNOT3 belongs to the Ccr4-Not complex, a conserved multi-
protein structure involved in the regulation of gene expression
[21].
To investigate if CNOT3 could influence PRPF31 expression, we
silenced its expression in ARPE-19 cell lines, by using two different
siRNA sequences. Suppression of CNOT3 resulted in significant
increase of PRPF31 mRNA and protein (p,0.001, Figure 2). This
effect was very specific, as no influence was observed in negative
controls and in TFPT expression, a neighboring gene sharing part
of the promoter with PRPF31 (Figure S2).
CNOT3-dependent modulation of PRPF31 expression is
achieved at the transcriptional level
CNOT3 can negatively regulate transcription by either directly
binding to the promoter of target genes or by affecting their
mRNA rate of degradation [22,23].
To understand which could be the mechanism through which
CNOT3 modulates PRPF31 expression, we incubated LCLs from
two asymptomatic-affected pairs with Actinomycin D, a drug that
inhibits de novo transcription, and then measured the rate of decay
of PRPF31 mRNA. No statistically significant difference was
observed between the asymptomatic and affected individuals
(Figure S3), suggesting that the modulation of PRPF31 expression
happens most probably at the transcriptional level.
CNOT3 binds directly to the PRPF31 promoter
To test this hypothesis, we performed a Chromatin Immuno-
Precipitation (ChIP) assay in LCLs from 3 healthy individuals,
using an anti-CNOT3 antibody and serum IgG as a negative
control. To confirm that CNOT3 enrichment of a target DNA
region was due to a specific immunoprecipitation rather than to a
random precipitation of DNA, we designed primers targeting
genomic regions that were not supposed to be bound by CNOT3.
Primers targeting CNOT3 promoter were used as a positive
control, since it has been previously shown that CNOT3 self-
regulates its expression by binding to its own promoter [23]. Both
qualitative and quantitative PCR showed a statistically significant
enrichment in PRPF31 promoter sequences in DNA that was
immunoprecipitated by the CNOT3 antibody, compared to that
exposed to serum IgG (Figure 3A, 3B).
CNOT3 rs4806718 alleles are associated with the clinical
manifestation of the disease
In order to identify genetic markers that could be associated
with variable expression of CNOT3 and therefore with penetrance
Author Summary
Retinitis pigmentosa (RP) is an inherited disorder of the
retina that is caused by mutations in more than 50 genes.
Dominant mutations in one of these, PRPF31, can be non-
penetrant. That is, some carriers of mutations suffer from
the disease while others do not display any symptoms. In
these particular individuals, functional PRPF31 transcripts
are expressed at higher levels compared to affected
persons, thus compensating for the deleterious effects of
the mutated allele. Up to now, the nature of such a
stochastic and protective effect was unknown. In this work,
we identify CNOT3 as the modifier gene responsible for
penetrance of PRPF31 mutations. We show that CNOT3 is a
negative regulator of PRPF31 expression and modulates
PRPF31 transcription by directly binding to its promoter. In
asymptomatic carriers of mutations, CNOT3 expression is
lower, allowing higher amounts of PRPF31 to be produced
and therefore inhibiting the development of symptoms.
Finally, we find that a polymorphism within a CNOT3
intronic region is associated with the clinical manifestation
of the disease.
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of PRPF31 mutations, we sequenced the entire CNOT3 genomic
region by next-generation sequencing (NGS) in one asymptomat-
ic-affected sibling pair. We identified five polymorphic variants
(rs36643, rs56079424, rs36661, rs4806718, rs1055234) that
differed between the two subjects. These five variants were
subsequently analyzed in a second asymptomatic-affected sibling
pair from the same pedigree, showing that only alleles of
rs4806718, lying in intron 17 of CNOT3, segregated with the trait.
Figure 1. CNOT3 shows an opposite trend of expression with respect to that of PRPF31 between the asymptomatic (AS) and affected
(AF) individuals of the AD5 family. (A) PRPF31 mRNA expression normalized to the housekeeping gene GAPDH. Error bars refer to the standard
deviation of the mean for 5 independent experiments for each group. (B) CNOT3 mRNA expression from the same 5 experiments used to generate
PRPF31 data. **, p,0.01. (C) Linear regression analysis of PRPF31 and CNOT3mRNA expression, which shows an inverse trend of the two genes in each
cell line. Circles, asymptomatic subjects; triangles, affected individuals; open symbols, CNOT3 expression; Filled symbols, PRPF31 expression. Data
having the same value for the x axis have been obtained from the same individual. (D) Quantification of CNOT3 protein abundance relative to b-actin
from 3 independent SDS-PAGE gels, after simultaneous detection of the two proteins by quantitative LI-COR western blot.
doi:10.1371/journal.pgen.1003040.g001
Figure 2. CNOT3 silencing stimulates PRPF31 expression in ARPE-19 cells. (A) CNOT3 mRNA depletion by 2 different siRNA sequences and its
effect on PRPF31 mRNA expression (B). ***, p,0.001. (C) Representative western blot of CNOT3 silencing and effect on PRPF31 protein expression.
siRNA_1 and siRNA_2, different CNOT3-specific siRNA sequences; Control, treatment with transfection reagent with no siRNA; Mock, treatment with
transfection reagent and scrambled siRNA.
doi:10.1371/journal.pgen.1003040.g002
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This SNP was then sequenced in a total of 38 asymptomatic and
affected individuals from the RP856/AD5 family, as well as from
an unrelated family for which the modifier gene for PRPF31
penetrance was also found to be linked to chromosome 19q13.4
[24] (Figure 4). Association between the C allele of rs4806718 with
the affected status and the T allele with the asymptomatic status
was moderately significant (p=0.04, by Fisher exact test).
Discussion
Despite penetrance being an old concept in genetics, little is
known about its molecular causes, especially in inherited human
diseases. Notable positive examples include dominant erythropoi-
etic protoporphyria, caused by mutations in the FECH gene, and
dominant elliptocytosis, due to mutations in SPTA1. In these
disorders, an imbalance of expression between the wild-type and
the mutated alleles causes the manifestation of the symptoms [25–
27].
Similar mechanisms determine penetrance of PRPF31 muta-
tions, since asymptomatic carriers are individuals who display
increased levels of wild-type mRNA alleles, which in turn
compensate for the deficiency caused by the mutation [16–18].
However, unlike erythropoietic protoporphyria and elliptocytosis,
in PRPF31-linked adRP the molecular causes of such beneficial
hyper-expression have remained, up to now, unexplained.
Previous mapping studies have shown that the penetrance and
expression of PRPF31 is influenced by at least two loci: one, likely
having a major effect, lies within the same chromosomal region as
Figure 3. CNOT3 binds to the PRPF31 promoter in cells. (A) CNOT3 ChIP-PCRs on different target sequences. Enrichment is visible only for
PRPF31 promoter and CNOT3 promoter (positive control); DHFR 39UTR, PTEN exon8, and GAPDH promoter sequences are all negative controls. (B)
CNOT3 ChIP-q-PCR on PRPF31 promoter sequence. Error bars indicate the standard deviation of the mean for three independent ChIP-qPCR
experiments. Serum IgG is used as IP negative control. ***, p,0.001.
doi:10.1371/journal.pgen.1003040.g003
Figure 4. Analysis of rs4806718 alleles in two unrelated pedigrees. (A) Family RP856/AD5. The individuals initially tested with NGS are
marked with a star. The individuals marked with a triangle belong to a sibship pair, which was previously shown by McGee et al. to have the same
isoallele haplotype but different phenotypes. (B) Family ADB1, a Bulgarian gypsy family carrying a heterozygous splice site mutation in PRPF31
(NM_015629.3:c.527+1G.T, or IVS6+1G.T). In both pedigrees carriers of mutations are either in black (affected individuals) or in grey (asymptomatic
individuals).
doi:10.1371/journal.pgen.1003040.g004
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PRPF31 (proximal modifier), the other is on chromosome 14
(distant modifier) [16,19]. Our previous work has also demon-
strated that both modifiers would act through diffusible elements
(e.g. transcription factors) since their effects on PRPF31 mRNA
expression concerns equally both copies of the gene [16]. This
observation probably explains the failure of previous attempts to
identify the proximal modifier as a polymorphic variant of the
PRPF31 sequence itself, according to the FECH or SPTA1 models.
Based on this previous knowledge, we reasoned that the
expression of the proximal modifier of PRPF31 mutations should
correlate with that of PRPF31. Therefore we started assessing
mRNA levels of genes that reside within the mapped 19q13.4
interval, by using the same cellular model successfully used in
previous studies of PRPF molecular genetics, and in particular of
PRPF31 penetrance [10,15–18,28,29]. Specifically, we studied
cells derived from members of one of the largest pedigrees known
to segregate a PRPF31 mutation, family RP856/AD5 [6,20], for
which incomplete penetrance could also be, at least in part,
determined by the proximal modifier [19]. Following a filtering
process based on both in silico analyses and on mRNA expression,
we were left with only 10 candidates. Of these, only one, CNOT3,
showed a pattern of expression that significantly correlated to that
of PRPF31. Interestingly, its trend of expression was inverse to that
of PRPF31, raising the possibility that CNOT3 may be a negative
regulator of PRPF31 expression.
CNOT3 encodes a protein that is part of the Ccr4-Not multi-
subunit complex, an evolutionary conserved multimeric structure
involved in modulation of gene expression [21,30–34]. Evidences
that CNOT3 could be a negative regulator of transcription have
been provided in yeast [31], and then confirmed in human cell
lines, by the identification of a conserved motif at its C-terminus,
called the Not-Box. This motif was originally identified in another
subunit of the complex, CNOT2, where it was shown to repress
reporter gene activity upon promoter targeting [35]. We
confirmed the role of CNOT3 as a negative regulator of PRPF31
expression by siRNA-mediated silencing experiments in ARPE-19
cells. Specifically, we observed that 70% depletion of CNOT3
induced approximately a 2-fold increase in PRPF31 expression,
but had no effects on TFPT, a gene that is contiguous to PRPF31
and shares with it part of the promoter [36].
CNOT3 can modulate transcription of its targets by the direct
binding to their promoters [23] or by promoting the recruitment
of deadenylases at the 39 end of their transcripts [22]. Our data
provide evidence showing that regulation of PRPF31 expression
should be mainly at the transcriptional level. First, we observed
that decay of PRPF31 mRNA was roughly the same in cells from
individuals expressing different levels of CNOT3, disfavoring gene
modulation through post-transcriptional mechanisms. Second, we
showed by ChIP that CNOT3 could bind directly to the bona fide
PRPF31 promoter.
In their work, McGee et al. identified the chromosomal interval
containing the proximal modifier through linkage analysis, a
technique that searches for relationships between phenotypes and
physical elements on the DNA sequence [19]. This implies that
variable expression of CNOT3 must be determined by a DNA
variant that is present in this same region, possibly within CNOT3
itself. Given their supposedly high frequency within the general
population, these isoalleles would very likely be polymorphic
elements. Our search for CNOT3 DNA changes that would be
present in asymptomatic but not in affected carriers of mutations
(or vice versa) resulted in the identification of particular alleles of
rs4806718.
Are these the isoalleles originally mapped by McGee et al.?
Although statistically significant, the association between
rs4806718’s C allele and disease (and the T allele with an
unaffected status) was not perfect. This phenomenon can be
explained by the presence of additional factors capable of
determining PRPF31 penetrance, such as the one mapped on
chromosome 14 [16]. These modifiers could interfere with or even
mask the effects of rs4806718 alleles, ultimately allowing the
‘‘wrong’’ rs4806718 variant to be associated with either pheno-
type. Such a hypothesis is in perfect agreement with the original
data on PRPF31 isoalleles, as a few discordant phenotype-
genotype associations concerning the mapped locus for the
proximal modifier were also clearly recognized. Amongst other
examples, 2 siblings from the last generation of RP856/AD5 had
discordant phenotypes but concordant haplotypes [19,37]. These
same individuals, genotyped by us at the rs4806718 locus, were
found indeed to share the same parental allele. Furthermore, if the
modifier allele is truly inherited from the parent who does not
transmit the mutation, then the chance that this does not forcibly
correspond to an rs4806718 allele is relatively high in RP856/
AD5, given the number of spouses external to the family who are
present in this pedigree.
Another important element to consider is whether rs4806718
alleles have a direct effect on CNOT3 expression, or whether the
two factors are simply in linkage disequilibrium with other
elements (e.g. transcription enhancers) lying somewhere else in
the region. According to in silico prediction tools, the rs4806718 C
variant, which has a frequency of 0.38 in the European
population, could affect CNOT3 splicing by decreasing the binding
energy for one acceptor splice site. Therefore, at least potentially,
rs4806718 alleles could represent the true PRPF31 isoalleles.
Taken together, all our observations suggest that CNOT3 is the
modifier gene on chromosome 19q13.4 that is responsible for
penetrance of PRPF31 mutations. Through direct repression of
PRPF31 transcription and in virtue of its own variable expression,
CNOT3 would differentially reduce the amount of available
PRPF31 mRNA, thus determining incomplete penetrance. Al-
though further studies on the physiological role of CNOT3 in
human cells and tissues are definitely needed, our data open the
way for a possible treatment of PRPF31-linked RP through the
inhibition of this transcriptional regulator.
Materials and Methods
Patients and cell lines
This study involved 10 individuals from the British family
RP856/AD5, segregating an 11-bp deletion in exon 11 of PRPF31
(c.1115_1125del) [6,20]. Our research has been conducted in
accordance with the tenets of the Declaration of Helsinki and has
been approved by the IRBs of our Institutions. Lymphoblastoid
cell lines derived from peripheral blood leukocytes of each
individual were either obtained from the Coriell Cell Repositories
or through the immortalization of peripheral blood leukocytes.
Cells were grown and maintained as previously described [18].
The human retinal pigment epithelial cell line ARPE-19 (kindly
provided by Dr. Yvan Arsenijevic) was grown and maintained at
37uC with 5% CO2 in N1 medium (DMEM/F12 complemented
with 2.5 mM L-glutamine, 56 mM NaHCO3, and 10% fetal
bovine serum).
RNA extraction and cDNA synthesis
Lymphoblasts were harvested during their exponential growth
phase (500,000–1,000,000 cells/ml) and RNAwas isolated from 107
cells using the QIAGEN RNeasy Mini Kit, following the
manufacturer’s instructions. The only modification to the protocol
concerned the DNase treatment, since we used double the amount
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of enzyme compared to the suggested quantity. RNA concentration
was measured with the Dropsense 96 spectrophotometer (Trinean).
cDNA synthesis was carried out as previously described [10].
q–PCR primer design and optimization
Most of the primer sequences used in this study were annotated
in the qPrimerDepot database (http://primerdepot.nci.nih.gov/).
These sequences are specifically designed to span exon-exon
junctions, thus avoiding genomic DNA to be amplified during q-
PCR. To design other primer sequences, which were not present
in the qPrimerDepot database, we used the Primer Blast tool from
NCBI (http://www.ncbi.nlm.nih.gov/tools/primer-blast/). To
validate each primer pair for q-PCR we first optimized the primer
amounts (50–200 nM), and then loaded 10 ml of the q-PCR
product obtained on a 1% agarose gel, in order to check the
specificity of the amplification product. Finally, a standard curve
using a control cDNA template was used to test each primer pair’s
efficiency. We considered as acceptable ranges of efficiency
between 90 and 110%, corresponding to standard curve slopes
between 23.6 and 23.1. All primer pairs used for this study are
listed in Table S2. For GAPDH and PRPF31 amplification we used
primers and probes previously described [16].
Real-time quantitative PCR
All genes but PRPF31 and GAPDH were amplified with the Sybr
Green PCR Master Mix (Applied Biosystems). Q-PCR reactions
were performed as published [16]. After having assessed that PCR
efficiencies for all genes were comparable, mRNA expression of
each of them was normalized with respect to GAPDH, using the
DDCt method.
Protein extraction
Total protein was extracted from lymphoblastoid cell lines in
RIPA buffer as reported before [10]. ARPE-19 whole cell lysate
was obtained by scraping the cells into 150 ml of lysis buffer
(20 mM Tris HCl, pH 8.0, 150 mM NaCl, 10% glycerol, 2 mM
EDTA, 1% TritonX-100) complemented with protease and
phosphatase inhibitors, and incubated on ice for 15 minutes
followed by a centrifugation at 14.000 rpm for 30 minutes at 4uC.
Proteins concentration was measured with the BCA protein assay
kit (Pierce), using BSA to generate a standard curve.
Western blot
Anti-PRPF31 antibody was raised in rabbit as previously
described [10]. Rabbit anti-CNOT3 antibody was purchased by
Bethyl Laboratories. This targets residues 525 to 575 of the human
CNOT3 protein (NP_055331.1), allowing detection of a 117-kDa
protein. Mouse anti-b-actin antibody (Sigma) was used as a
loading control.
Equal amounts of proteins were loaded and run on an 8% SDS-
PAGE gel. Proteins were transferred to a nitrocellulose membrane
and blocked in 5% milk overnight at 4uC or alternatively for
1 hour at room temperature. The incubation of all primary
antibodies was performed for 1 hour at room temperature using
the following dilutions: anti-PRPF31 (1:500), anti-CNOT3
(1:2,000), and anti-b-ACTIN (1:2,500). The membrane was
washed 3 times with 0.05% Tween-20 in TBS. Rabbit and mouse
HRP-conjugated secondary antibodies were diluted 1:1,000 in 2%
milk and incubated for 1 hour at room temperature. Bands were
detected using enhanced chemioluminescence (Pierce).
Signal detection via the Odyssey infrared imaging system (LI-
COR) was performed by using fluorescently-labeled secondary
antibodies provided by LI-COR, diluted 1:5,000 in 0.5% milk and
incubated in the dark, for 1 hour at room temperature. The
membrane was then washed twice with 0.05% Tween-20 in TBS
and once in PBS to remove residual Tween-20 prior to the laser
scanning.
In vitro silencing experiments
We used two different siRNA sequences targeting CNOT3
(QIAGEN, FlexiTube siRNA, Hs_CNOT3_5 and
Hs_CNOT3_8, 1 nmol) and a negative control siRNA for human
genes (Santa Cruz Biotechnology). One day before transfection
ARPE-19 cells were seeded at a concentration of 26105 cells/well
in a 6 well-plate, and transfection was achieved by using 5 ml
Lipofectamine (Invitrogen) and 50 pmol siRNA. RNA was
extracted 48 hrs after transfection.
Actinomycin D treatment of cells
Lymphoblasts grown at a concentration of ,8 million cells in a
T75 flask were treated with Actinomycin D (5 mg/ml in DMSO)
(Sigma) by adding it directly to the medium. Cell pellets were
collected at seven different time points (0–24 hrs) and total RNA
was extracted and analyzed by q-PCR.
Chromatin immunoprecipitation (ChIP)
Three control lymphoblastoid cells from the Centre d’Etude du
Polymorphisme Humain (CEPH) were grown to have 107 cells per
ChIP experiment. DNA and proteins were cross-linked by adding
1% formaldehyde directly to the medium and by incubating the
cells on a rotating hybridization oven at 37uC for 10 minutes. To
quench cross-linking, we then added 125 mM glycine and
incubated the cells at 37uC for 5 minutes. Cells were pelleted by
centrifugation (800 g for 5 minutes at 4uC) and washed twice with
cold PBS, supplemented with protease inhibitors. Optimization of
the chromatin shearing was performed by using a Covaris
sonicator, to obtain on average cross-linked DNA fragments of
150–400 bp. ChIP was performed using buffers provided with the
Ep-iT Chromatin Immunoprecipitation kit (Bio-AAA). Immuno-
precipitation was performed using three different antibodies: anti-
CNOT3, anti-pol2 (Bio-AAA) as a positive control for IP, and
serum IgG (Santa Cruz Biotechnology) as a negative control for
IP. Antibody-protein-DNA complexes were collected on protein A
agarose beads (2 hrs, 4uC), then washed with the low salt buffer,
high salt buffer, LiCl buffer, and TE buffer (pH 8.0) provided in
the kit to remove non-specific binding. Complexes were eluted
from the beads by using the elution buffer (0.1 mM NaHCO3 and
1% SDS) in an orbital shaker. Cross-links were removed by an
overnight incubation at 65uC. Ribonuclease and proteinase K
digestion were added to remove specific contaminants, before the
eluted DNA was extracted once in 25:24:1 phenol-chloroform-
isoamyl alcohol and once in 24:1 chloroform-isoamyl alcohol.
DNA was ethanol precipitated, washed in 70% ethanol, and finally
eluted in TE.
ChIP-PCR was performed using the GoTaq DNA Polymerase
(Promega) and 0.5 ml of the ChIP DNA, by using standard cycling
conditions and primers described in Table S3. GAPDH primer
sequences are the ones provided by Millipore for the EZ-ChIP kit,
while primers for DHFR have been previously described [38].
Two microliters of ChIP DNA were also amplified by q-PCR
using Sybr Green PCR Master Mix (Applied Biosystems) and the
PRPF31 promoter primer pair (Table S3).
Ultra-high-throughput sequencing
CNOT3 genomic region was amplified by 3 overlapping long-
range PCRs (Table S4), for a total length of 34 Kb. PCR was
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performed in 20 ml using TaKaRa LA Taq and GC buffer I
(Takara Bio Inc.). Final primers concentration was 1 mM, and
200 ng of genomic DNA were used as template. PCR amplifica-
tion conditions were: an initial step at 94uC for 1 minute, 30 cycles
of denaturation at 98uC for 5 seconds and annealing/extension at
68uC for 15 minutes, and a final extension step at 72uC for
10 minutes. Long-range PCR products were sequenced with an
Illumina HiSeq 2000 machine, to obtain coverage values in the
range of thousands of reads. Mapping of the reads and variant
detection was performed by using the CLCbio Genomics
Workbench software.
Statistical analysis
Differences of gene expression between asymptomatic and
affected individuals were tested by t-test, and likelihood computed
by 100 Monte Carlo label-swapping simulations per each gene.
One-way ANOVA followed by Bonferroni’s multiple compar-
ison tests was used to analyze the effect of CNOT3 silencing on the
expression of the target genes. The enrichment of PRPF31
promoter sequence after CNOT3 immunoprecipitation compared
to the serum IgG was evaluated by using the Mann Whitney non-
parametric statistical hypothesis test.
In figures, p,0.05 is indicated by one star, p,0.01 by 2 stars,
and p,0.001 by 3 stars.
Supporting Information
Figure S1 Gene expression analysis of candidate genes in LCLs
derived from asymptomatic (AS) and affected (AF) carriers of
mutations. mRNA expression of each gene is normalized to the
housekeeping gene GAPDH. Error bars refer to the standard
deviation of the mean for each group.
(PDF)
Figure S2 Effect of CNOT3 silencing on the mRNA expression
of two housekeeping genes and TFPT, in ARPE-19 cells. The data
presented here are from the same experiments shown in Figure 2.
Depletion of CNOT3 has no effects on the mRNA expression of
these control genes. Mock, scrambled siRNA sequence; siRNA_1
and siRNA_2, sequences specific for CNOT3; Control, cells treated
with no siRNA. Error bars refer to the standard deviation of the
mean for three independent experiments.
(PDF)
Figure S3 PRPF31 mRNA decay in LCLs from asymptomatic
and affected carriers of mutations, following treatment with
actinomycin D. mRNA half-life is similar in both groups. Error
bars refer to the standard deviation of the mean at different time
points for at least three independent experiments.
(PDF)
Table S1 Lymphoblastoid cell lines from the RP856/AD5
family used in this work.
(PDF)
Table S2 Primers for q-PCR amplification. Annealing temper-
ature for all primers is 60uC.
(PDF)
Table S3 Primers for ChIP-PCR.
(PDF)
Table S4 Primers for CNOT3 long-range PCR amplification.
(PDF)
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